Key expertise includes clinical development within orphan, neuromuscular, neurology and oncology indications. Carl has a solid record of global leadership, including two IPOs on Nasdaq OMX, agreed clinical plans with FDA, EMA and PMDA, successful completion of phase I-IV studies, and new drug approvals. He received his MD and Ph.D. from the Faculty of Health Sciences, University of Linköping, Sweden, and was subsequently a Postdoctoral Fellow at the Department of Neurosciences, Cleveland Clinic Foundation, Cleveland, OH, USA 1998-2002. Carl joined the pharmaceutical industry as a Specialist at Lundbeck A/S 2002-2008.
Thereafter he became Senior Medical Director at Genzyme, a Sanofi company 2008-2015, leading neurology and orphan neuromuscular development programs. Between 2015 and 2018 Carl was CMO at Wilson Therapeutics AB, Stockholm, Sweden (acquisition by Alexion Pharmaceuticals in 2018 at 70% premium - USD 850m). He subsequently was CMO at Ascelia Pharma AB, Malmö, Sweden 2018-2022. From 2023 Carl has worked as an independent consultant at BjartmarMed AB. He is a Board member of iCoat Medical AB and has authored more than 30 international publications (peer-reviewed articles, review articles, book chapters).